This presentation will summarize the epidemiological evidence relating to the descriptive and analytical epidemiology of FM, and recent studies of its management. Historically classified using a combination of chronic widespread pain and widespread tenderness, over recent years a number of new classification criteria have been suggested, redefining the condition taking more consideration of multiple common (somatic) symptoms. This presentation will: (i) discuss recent proposals regarding the classification of FM; differences between the proposed clinical and research criteria; and the distinction between FM and chronic widespread pain; (ii) summarize the data estimating the prevalence of FM and chronic widespread pain in the general population; (iii) provide an overview of the epidemiological evidence relating to the onset and prognosis of the FM/chronic widespread pain; and finally, (iv) discuss the evidence from recent randomized controlled trials informing the management of the condition(s). Disclosure statement: The author has declared no conflicts of interest.
This presentation will summarize the epidemiological evidence relating to the descriptive and analytical epidemiology of FM, and recent studies of its management. Historically classified using a combination of chronic widespread pain and widespread tenderness, over recent years a number of new classification criteria have been suggested, redefining the condition taking more consideration of multiple common (somatic) symptoms. This presentation will: (i) discuss recent proposals regarding the classification of FM; differences between the proposed clinical and research criteria; and the distinction between FM and chronic widespread pain; (ii) summarize the data estimating the prevalence of FM and chronic widespread pain in the general population; (iii) provide an overview of the epidemiological evidence relating to the onset and prognosis of the FM/chronic widespread pain; and finally, (iv) discuss the evidence from recent randomized controlled trials informing the management of the condition(s). Disclosure statement: The author has declared no conflicts of interest. Results: On average, the superiority of antidepressants, anticonvulsants, CBT, MTs over controls is small from a statistical point of view. Drug and non-drug therapies do not differ in the reduction of pain and improvement of quality of life in indirect comparisons. Data on sustained positive effects (follow-up assessments) are only available for AE, CBT and MTs, but not for drug therapy. There is no conclusive evidence that CAM therapies such as acupuncture or homeopathy are superior to sham therapies. The external validity of most drug RCTs is limited because of the exclusion of patients with inflammatory rheumatic diseases and mental disorders. German FM consumers attributed a more favourable benefit-harms ratio to non-drug therapies including CAM therapies than to drug therapy. There was no clinical average benefit of duloxetine, milnacipran and pregabalin compared with prior therapy in FM patients of the National Data Bank of Rheumatic Diseases. Meta-analyses reporting small effect sizes might lead to an underestimation of the potential effects of FM therapies in clinical practice. The small effect sizes are due to the fact, that drug placebo or attention controls reduce FM symptoms too. Whereas investigators try to minimize placebo effects, these unspecific (contextual) factors should be maximized in clinical care, e.g. by strengthening positive treatment expectations and establishing an empathic doctor-patient relationship. Availability, safety, potential side effects and costs are additional points to consider when consulting FM patients on treatment options. Duloxetine, milnacipran and pregabalin have not been approved for FM by the European Medicines Agency. Severe side effects are rare, but happen with drug therapy. AE is available everywhere at low cost, in contrast to CBT and MTs. Conclusion: There is no therapy that works in every FM patient. Some therapies, e.g. CAM methods, which are not superior to sham therapies in RCTs, might work well in some patients in routine clinical care. First line evidence-based long-term treatments of FM are selfmanagement strategies (AE, stress reduction). Preferences and comorbidities of patients should be considered in the selection of treatment options. It is the task of the physician to identify treatment responders. Maintaining and improving daily function and satisfaction with life might be more appropriate treatment goals than symptom reduction. Disclosure statement: W.H. has received honoraria from DaiichiSankyo, Abbott Germany and Pfizer; and funding for research from the German League for People with Arthritis and Rheumatism.
I40. UNDERSTANDING MECHANISMS IN THE

MANAGEMENT OF DIFFICULT LUPUS I42. MANAGEMENT OF CARDIOVASCULAR RISK
Ian Bruce In SLE, pleuritis is easily the most prevalent pulmonary manifestation. Chronic interstitial lung disease is infrequent, with a life-time prevalence of perhaps 5%. All individual histological patterns reported in idiopathic interstitial pneumonia can occur in SLE but fibrotic patterns [nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP)] predominate. Probably, NSIP is more prevalent but in reality, clinicians seldom perform surgical lung biopsies in interstitial lung disease in CTD. Therefore, optimal management involves the evaluation of clinical and HRCT features, rather than reliance on identification of a specific histological pattern. Essentially, based on the selection of management and monitoring strategies, there are five patterns of interstitial lung disease (self-limited and reversible; stable and irreversible; major reversible disease, often with progression to irreversible disease; progressive irreversible disease in which stabilization with treatment can be achieved; and inexorably progressive irreversible disease). These distinctions, discussed in greater detail during the presentation, are based on severity, CT appearance and observed disease behaviour. When uncertainties exist at initial assessment, it is usually possible to reduce the possible disease behaviour diagnoses in an individual patient to just two of the five possibilities. Generally, the disease behaviour category becomes clearer with short term observation including an evaluation of responsiveness to initial treatment. Treatments of interstitial lung disease in SLE are reviewed. The selection of therapies is largely based on limited literature in other CTDs (especially SSc) in which lung disease is more prevalent than in SLE. Treatment options are limited but Rituximab may add usefully to traditional therapies (corticosteroids and standard immunosuppressive agents). Pulmonary vasculitis should always be considered, especially when there is undue
